JP Morgan Chase’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,732
| Closed | -$1.94K | – | 7571 |
|
|
2025
Q2 | $1.94K | Sell |
1,732
-8,206
| -83% | -$10K | ﹤0.01% | 6544 |
|
|
2025
Q1 | $11.4K | Buy |
9,938
+127
| +1% | +$236 | ﹤0.01% | 6272 |
|
|
2024
Q4 | $59.9K | Buy |
9,811
+3,024
| +45% | +$35.9K | ﹤0.01% | 5946 |
|
|
2024
Q3 | $112K | Sell |
6,787
-286
| -4% | -$3.13K | ﹤0.01% | 5648 |
|
|
2024
Q2 | $48.6K | Buy |
7,073
+1,237
| +21% | +$10.6K | ﹤0.01% | 5872 |
|
|
2024
Q1 | $56.3K | Sell |
5,836
-3,908
| -40% | -$45.3K | ﹤0.01% | 5889 |
|
|
2023
Q4 | $81K | Sell |
9,744
-4,531
| -32% | -$26.3K | ﹤0.01% | 5829 |
|
|
2023
Q3 | $119K | Buy |
14,275
+3,331
| +30% | +$28.3K | ﹤0.01% | 5374 |
|
|
2023
Q2 | $101K | Sell |
10,944
-2,856
| -21% | -$32K | ﹤0.01% | 5458 |
|
|
2023
Q1 | $190K | Buy |
13,800
+2,585
| +23% | +$53.5K | ﹤0.01% | 5094 |
|
|
2022
Q4 | $191K | Buy |
11,215
+223
| +2% | +$4.46K | ﹤0.01% | 5055 |
|
|
2022
Q3 | $250K | Buy |
10,992
+1,031
| +10% | +$20.8K | ﹤0.01% | 4841 |
|
|
2022
Q2 | $180K | Sell |
9,961
-1,671
| -14% | -$29.8K | ﹤0.01% | 5130 |
|
|
2022
Q1 | $312K | Buy |
11,632
+4,115
| +55% | +$76.6K | ﹤0.01% | 4959 |
|
|
2021
Q4 | $220K | Buy |
7,517
+862
| +13% | +$42.8K | ﹤0.01% | 5298 |
|
|
2021
Q3 | $437K | Buy |
6,655
+681
| +11% | +$52.1K | ﹤0.01% | 4809 |
|
|
2021
Q2 | $497K | Buy |
5,974
+1,561
| +35% | +$116K | ﹤0.01% | 4700 |
|
|
2021
Q1 | $338K | Buy |
4,413
+840
| +24% | +$76.5K | ﹤0.01% | 4901 |
|
|
2020
Q4 | $315K | Buy |
3,573
+927
| +35% | +$65.2K | ﹤0.01% | 4624 |
|
|
2020
Q3 | $198K | Buy |
2,646
+252
| +11% | +$14.9K | ﹤0.01% | 4366 |
|
|
2020
Q2 | $175K | Buy |
2,394
+806
| +51% | +$49K | ﹤0.01% | 4319 |
|
|
2020
Q1 | $89K | Sell |
1,588
-27
| -2% | -$1.18K | ﹤0.01% | 4557 |
|
|
2019
Q4 | $62K | Buy |
+1,615
| New | +$40.6K | ﹤0.01% | 5053 |
|
Other funds holding IGMS
JP Morgan Chase's IGMS Position: Q3 2025 in Review
JP Morgan Chase sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 1,732 shares — an estimated $1.94K sold.
JP Morgan Chase first reported a position in IGMS in Q4 2019 and held it in 23 quarters. The position peaked at $497K in Q2 2021. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- JP Morgan Chase reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- JP Morgan Chase sold 1,732 IGM Biosciences shares in Q3 2025, an estimated $1.94K.
- JP Morgan Chase first reported a position in IGM Biosciences in Q4 2019 and held it in 23 quarters.
- JP Morgan Chase's IGM Biosciences position peaked at $497K in Q2 2021.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.